Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its participation in two upcoming investor events: the Microcap Rodeo: Windy City Roundup 2022 on October 12, 2022, and the LD Micro Main Event XV on October 26, 2022. At these events, the company will showcase its innovative dermatology products, including the XTRAC^® and TheraClear^® systems, which target conditions like psoriasis, acne, and vitiligo, impacting over 31 million patients in the U.S. STRATA employs a unique Direct to Consumer advertising model to boost awareness and patient volume for its partner dermatology clinics.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 3:30 PM ET. The event will be virtual, and management will present innovative advancements in dermatologic treatment technologies. Interested individuals can access the presentation via a live webcast through a provided link, with an archived version available on the company’s website post-event. STRATA focuses on developing treatments for conditions such as psoriasis and acne, impacting millions across the U.S.

STRATA Skin Sciences (NASDAQ: SSKN) reported second-quarter 2022 revenues of $9.1 million, a 23% increase from the previous year. Global recurring revenues remained stable at $5.6 million. The company launched TheraClear®X targeting the $5.5 billion acne care market. However, gross profit decreased to $5.0 million (55% margin) from $4.8 million (65% margin) due to higher amortization costs. A net loss of $1.9 million was recorded, compared to a net income of $1.1 million in Q2 2021. For 2022, STRATA anticipates revenue of $33.0 million to $35.0 million, indicating 10% to 17% growth.

STRATA Skin Sciences (NASDAQ: SSKN) announced the upcoming Key Opinion Leader (KOL) Call hosted by Ladenburg Thalmann on August 16, 2022, at 11:00 AM ET. Dr. Benjamin Lockshin will discuss the growing markets for psoriasis and vitiligo, emphasizing the role of STRATA’s XTRAC Excimer Laser in treatment outcomes. The call aims to highlight the company's innovative technologies, which include the XTRAC and Pharos excimer lasers and TheraClear X Acne Therapy System. Registration details for the live call are available on STRATA's website.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced plans to release its second quarter 2022 financial results on August 10, 2022, at 4:30 p.m. ET. The company will host a conference call to discuss these results and provide a corporate update, which will be available via webcast. STRATA specializes in developing and marketing innovative medical technologies for dermatologic conditions, including psoriasis and acne. Their offerings include excimer lasers and the new TheraClear®X Acne Therapy System.

STRATA Skin Sciences (NASDAQ: SSKN) has launched TheraClearX, a non-invasive acne treatment system, aimed at the $5.5 billion acne care market. The device utilizes a combination of vacuum technology and intense broadband light to target mild to moderate acne types. CEO Bob Moccia expressed confidence that this innovation will provide both dermatologists and patients with promising new treatment options, while contributing to the company's growth through its Partnership Program.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leader in dermatologic medical technology, will participate in the Lytham Partners Summer 2022 Investor Conference on June 21-22, 2022. This virtual event will include one-on-one meetings with management, aimed at enhancing investor engagement.

STRATA focuses on innovative treatment solutions for various skin conditions, including psoriasis and acne, through products like the XTRAC and TheraClear systems. The company’s unique business model emphasizes Direct to Consumer advertising to grow its partner dermatology clinics.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has appointed Michael E. Goodman as its Head of International Sales, a newly created position aimed at enhancing the company's global market presence. Goodman, who has nearly two decades of experience in medical laser sales, will lead strategies across Europe, Asia, and Latin America. His role involves providing insights for successful international sales expansion. STRATA develops innovative dermatologic products, including excimer lasers for treating skin conditions affecting over 31 million U.S. patients.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q1 2022 revenue of $7.0 million, a 21% increase from Q1 2021. Gross profit was $4.1 million (59% of revenues), down from 64% YoY. The company recorded a net loss of $2.5 million, equivalent to a loss of $0.07 per share. The installed base of XTRAC devices reached 903. Strata anticipates 2022 revenues between $33 million and $35 million, reflecting an expected 10%-17% growth. The company plans to launch a new FDA-approved product in Q3 2022 and expand into new markets globally.